Equities

Thor Medical ASA

Thor Medical ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)1.02
  • Today's Change0.002 / 0.20%
  • Shares traded121.03k
  • 1 Year change-28.07%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Thor Medical ASA share price to rise to 11.00 in the next year from the last price of 1.02.
High978.4%11.00
Med978.4%11.00
Low978.4%11.00

Earnings history & estimates in NOK

Earnings forecasts are not available for Thor Medical ASA. On Aug 31, 2022, Thor Medical ASA reported 2nd quarter 2022 losses of -- per share.
Average growth rate-15.17%
Thor Medical ASA reported annual 2021 losses of -4.65 per share on Mar 01, 2022.
Average growth rate+3.84%
More ▼

Revenue history & estimates in NOK

Nordic Nanovector ASA did not report revenues for the 2nd quarter 2022. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Nordic Nanovector ASA did not report revenues for the full year 2021. However, during the prior year the company reported revenues of 0.00.
Average growth rate-25.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.